Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the treatment of newly diagnosed AL amyloidosis: Impact of response on survival outcomes

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) is an effective regimen for the treatment of patients with newly diagnosed AL amyloidosis however, it remains inadequate to enhance outcomes in high risk groups and minimal information is available on the impact of minimal residual disease (MRD) in overall survival. Hematological and Organ Response was assessed in newly diagnosed AL amyloidosis treated with CyBorD. Results showed a ≥VGPR rate of 53% with 26.5% achieving CR. In addition, MRD negativity assessed by MPF in patients with CR resulted in no difference on survival outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research